Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor

Member of:

    ORCID: 0000-0003-2611-5642

    Publication year:
    All
    41 - 50 out of 236Page size: 10
    Sort by: 1st author
    1. Published

      Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects.

      Deacon, Carolyn F., Nauck, M. A., Nielsen, M. T., Pridal, L. & Holst, Jens Juul, 1995, In: Diabetes. 44, p. 1126-1131

      Research output: Contribution to journal › Journal article › Research › peer-review

    2. Published

      Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

      Deacon, Carolyn F., Danielsen, P., Klarskov, L., Holst, Jens Juul & Olesen, M., 2001, In: Diabetes. 50, p. 1588-1597

      Research output: Contribution to journal › Journal article › Research › peer-review

    3. Published

      Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

      Deacon, Carolyn F., Hughes, T. E. & Holst, Jens Juul, 1998, In: Diabetes. 47, p. 764-769

      Research output: Contribution to journal › Journal article › Research › peer-review

    4. Published

      Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes

      Deacon, Carolyn F., Holst, Jens Juul & Carr, R. D., 1999, In: Drugs of Today. 35, p. 159-170

      Research output: Contribution to journal › Journal article › Research › peer-review

    5. Published

      What do we know about the secretion and degradation of incretin hormones?

      Deacon, Carolyn F., 2005, In: Regulatory Peptides. 128, 2, p. 117-24 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    6. Published

      Potential of liraglutide in the treatment of patients with type 2 diabetes

      Deacon, Carolyn F., 2009, In: Vascular Health and Risk Management (Online). 5, 1, p. 199-211 12 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    7. Published

      MK-431 (Merck).

      Deacon, Carolyn F., 2005, In: Current Opinion in Investigational Drugs. 6, 4, p. 419-26 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    8. Published

      Immunoassays for the incretin hormones GIP and GLP-1

      Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    9. Published

      Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

      Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    10. Published

      Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

      Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    Previous 1 2 3 4 5 6 7 8 ...24 Next

    ID: 9220